 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
17 News |  |
- |||| TOP1288 / Topivert
Trial completion, Enrollment change: Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis (clinicaltrials.gov) - Jul 7, 2017
P2a, N=77, Completed, Sponsor: Topivert Pharma Ltd
Recruiting --> Completed | N=60 --> 77
- |||| TOP1288 / Topivert
Enrollment open: Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis (clinicaltrials.gov) - Oct 4, 2016
P2a, N=60, Recruiting, Sponsor: Topivert Pharma Ltd
Recruiting --> Completed | N=60 --> 77 Not yet recruiting --> Recruiting
- ||| TOP1288 / Topivert
Trial completion: Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects (clinicaltrials.gov) - Sep 15, 2016
P1, N=70, Completed, Sponsor: Topivert Pharma Ltd
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| TOP1288 / Topivert
New P2a trial: Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis (clinicaltrials.gov) - Sep 6, 2016
P2a, N=60, Not yet recruiting, Sponsor: Topivert Pharma Ltd
- || TOP1288 / Topivert
Trial primary completion date: Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects (clinicaltrials.gov) - May 11, 2016
P1, N=70, Recruiting, Sponsor: Topivert Pharma Ltd
Recruiting --> Completed Trial primary completion date: Jan 2016 --> Jul 2016
- TOP1288 / Topivert
New P1 trial: Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects (clinicaltrials.gov) - Jun 4, 2015
P1, N=70, Recruiting, Sponsor: Topivert Pharma Ltd